1-(5-溴-1-苯并噻吩-3-基)乙酮 | 1423-63-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻吩类
• 中文名称: 1-(5-溴-1-苯并噻吩-3-基)乙酮
• 中文别名: 3-乙酰基-5-溴苯并噻吩
• 英文名称: 1-(5-bromobenzo[b]thiophen-3-yl)ethan-1-one
• 英文别名: 1-(5-bromobenzo[b]thiophen-3-yl)ethanone；3-acetyl-5-bromobenzo[b]thiophene；1-(5-bromo-benzo[b]thiophen-3-yl)-ethanone；3-acetyl-5-bromo-benzothiophene；3-Acetyl-5-brom-benzothiophen；1-(5-bromo-1-benzothiophen-3-yl)ethanone
• CAS: 1423-63-8
• 化学式: C₁₀H₇BrOS
• 分子量: 255.135
• InChiKey: IRGMTUHYELTYEG-UHFFFAOYSA-N

物化性质

• 熔点：
  112-113°C
• 沸点：
  359.7±22.0 °C(Predicted)
• 密度：
  1.587±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  45.3
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险类别码：
  R20/21/22
• 海关编码：
  2934999090

SDS

Name:	1-(5-Bromo-1-benzothien-3-yl)ethanone Material Safety Data Sheet
Synonym:
CAS:	1423-63-8

Section 1 - Chemical Product MSDS Name:1-(5-Bromo-1-benzothien-3-yl)ethanone Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
1423-63-8	1-(5-Bromo-1-benzothien-3-yl)ethanone	97+%	unlisted

Hazard Symbols: XN
Risk Phrases: 20/21/22 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful by inhalation, in contact with skin and if swallowed.
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
Causes skin irritation. Harmful if absorbed through the skin.
Ingestion:
Harmful if swallowed. May cause irritation of the digestive tract.
Inhalation:
Harmful if inhaled. Causes respiratory tract irritation.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid. Get medical aid immediately.
Skin:
Get medical aid. Get medical aid immediately. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Do not induce vomiting. Get medical aid. Get medical aid immediately. Wash mouth out with water.
Inhalation:
Get medical aid immediately. Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use foam, dry chemical, or carbon dioxide. Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes. Do not breathe dust, vapor, mist, or gas. Do not get in eyes, on skin, or on clothing. Use only in a chemical fume hood.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 1423-63-8: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: Off White
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 112 - 113 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C10H7BrOS
Molecular Weight: 255.13

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents, bases, amines, halogens.
Hazardous Decomposition Products:
Carbon monoxide, oxides of sulfur, carbon dioxide, hydrogen bromide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 1423-63-8 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
1-(5-Bromo-1-benzothien-3-yl)ethanone - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.*
Hazard Class: 6.1
UN Number: 2811
Packing Group: III
IMO
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2811
Packing Group: III
RID/ADR
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2811
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 20/21/22 Harmful by inhalation, in contact with
skin and if swallowed.
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 22 Do not breathe dust.
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
WGK (Water Danger/Protection)
CAS# 1423-63-8: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 1423-63-8 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 1423-63-8 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-(5-溴-1-苯并噻吩-3-基)乙酮 在 titanium(IV) tetraethanolate 、 copper(l) iodide 、 (1R,2R)-(-)-N,N'-二甲基-1,2-环己二胺 、 sodium carbonate 、 potassium carbonate 、 三氟乙酸 、 间苯二甲醚 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 甲苯 为溶剂， 反应 54.17h， 生成 (R)-4-fluoro-N-(3-(1-(N-methylsulfamoyl)-2-thioureidopropan-2-yl)benzo[b]thiophen-5-yl)benzamide
  参考文献：
  名称：

  亚氨基噻二嗪二氧化物衍生物及其用途

  摘要：

  本发明公开了亚氨基噻二嗪二氧化物衍生物及其用途，具体地，本发明涉及一类新颖的亚氨基噻二嗪二氧化物衍生物以及包含该类化合物的药物组合物，它们可作为BACE‑1抑制剂。本发明还涉及制备这类化合物和药物组合物的方法，以及它们在制备治疗与β‑淀粉样蛋白(“Aβ”)有关的疾病，特别是阿尔茨海默病的药物中的用途。

  公开号：

  CN109796447B
• 作为产物：
  描述：

  (4-溴苯)(2,2-二甲氧基乙基)硫 在 四氯化锡 作用下， 以 1,2-二氯乙烷 、 氯苯 为溶剂， 反应 35.0h， 生成 1-(5-溴-1-苯并噻吩-3-基)乙酮
  参考文献：
  名称：

  一类新型的，有效的，选择性的和口服活性的前列腺素D2受体拮抗剂的各种衍生物的合成和生物活性。2.6，6-二甲基双环[3.1.1]庚烷衍生物。

  摘要：

  在较早的论文中，我们报道了以双环[2.2.1]庚烷环系统为前列腺素骨架的新型前列腺素D（2）（PGD（2））受体拮抗剂是一种有效的新型抗过敏剂，可抑制各种过敏性炎症诸如在结膜炎和哮喘模型中观察到的反应。在本研究中，我们合成了具有6,6-二甲基双环[3.1.1]庚烷环系统的PGD（2）受体拮抗剂。与具有磺酰胺基的双环[2.2.1]庚烷环系统的那些相反，这些衍生物具有酰胺部分。具有6,6-二甲基双环[3.1.1]庚烷环的衍生物在PGD（2）受体结合和cAMP形成分析中也显示出强大的活性。在诸如过敏性鼻炎，结膜炎和哮喘模型等体内分析中，这些系列的衍生物显示出优异的药理特性。特别地，化合物45在过敏性鼻炎和哮喘模型中也有效抑制了嗜酸性粒细胞的浸润。该化合物（45，S-5751）现在正被开发为一种有前途的抗过敏药物候选物。

  DOI：

  10.1021/jm0205189

文献信息

• Hydrogen bond donor solvents enabled metal and halogen-free Friedel–Crafts acylations with virtually no waste stream
  作者：Guangchang Liu、Bo Xu

  DOI：10.1016/j.tetlet.2018.01.026

  日期：2018.3

  halogen-free Friedel–Crafts acylation protocol with virtually no waste stream generation. We propose a hydrogen bonding donor solvent will form a hydrogen bonding network and may provide significant rate enhancement for Friedel–Crafts reactions. Trifluoroacetic acid is one of the strongest H-bond donor solvents, which is also volatile and can be easily recovered by distillation without need for reaction workup

  我们已经开发了一种无金属，无卤素的Friedel-Crafts酰化方案，几乎没有废物流产生。我们建议氢键供体溶剂将形成氢键网络，并可能显着提高Friedel-Crafts反应的速率。三氟乙酸是最强的氢键供体溶剂之一，它也是易挥发的，可以通过蒸馏容易地回收而无需进行反应后处理。我们的方案是“绿色”的Friedel-Crafts酰化工艺：1）催化剂可以回收再利用；2）使用无卤素的起始原料（羧酸酐或羧酸）；3）无需进行水相反应后处理；4）最少或没有废蒸汽产生。
• FUNCTIONALLY SELECTIVE ALPHA2C ADRENORECEPTOR AGONISTS
  申请人：De lera Ruiz Manuel

  公开号：US20100197562A1

  公开（公告）日：2010-08-05

  In its many embodiments, the present invention provides a novel class of biaryl compounds as inhibitors of ÿ2C adrenergic receptor agonists, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the ÿ2C adrenergic receptors using such compounds or pharmaceutical compositions.

  在其多种实施方式中，本发明提供了一类新型的联苯化合物，作为ÿ2C肾上腺素受体激动剂的抑制剂，以及制备这种化合物的方法、含有一种或多种这种化合物的药物组合物、制备含有一种或多种这种化合物的药物配方的方法，以及使用这种化合物或药物组合物治疗、预防、抑制或改善与ÿ2C肾上腺素受体相关的一种或多种病症的方法。
• Compounds, pharmaceutical compositions, and methods for inhibiting protein kinases
  申请人：——

  公开号：US20020006952A1

  公开（公告）日：2002-01-17

  Amino-pyrazole compounds that modulate and/or inhibit the activity of protein kinases. These compounds and pharmaceutical compositions containing them are capable of mediating and/or inhibiting the activity cyclin-dependent kinases, thereby modulating and/or inhibiting unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating cancer as well as other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.

  氨基吡唑化合物，可调节和/或抑制蛋白激酶的活性。这些化合物和含有它们的药物组成物能够介导和/或抑制周期依赖性激酶的活性，从而调节和/或抑制不必要的细胞增殖。该发明还涉及含有这种化合物的药物组成物的治疗或预防用途，以及通过给予有效量的这种化合物的方法来治疗癌症以及与不必要的血管生成和/或细胞增殖相关的其他疾病状态，如糖尿病视网膜病变、新生血管性青光眼、类风湿性关节炎和银屑病。
• Process for preparing 5-hydroxybenzo [b] thiophene-3-carboxylic acid derivatives
  申请人：——

  公开号：US20020026061A1

  公开（公告）日：2002-02-28

  Benzothiophenecarboxylic acid derivatives of the formula (I) which are useful as starting materials for producing drugs, and a process for preparing 5-hydroxybenzo[b]-thiophene-3-carboxylic acid derivatives of the formula (VI) which are specific PGD 2 antagonists. 1

  式(I)的苯并噻吩羧酸衍生物可以作为制药原料，而式(VI)的5-羟基苯并[b]-噻吩-3-羧酸衍生物是特异的PGD2拮抗剂，制备方法如下。
• PROCESS FOR PREPARING 5-HYDROXYBENZO [B] THIOPHENE-3-CARBOXYLIC ACID DERIVATIVES
  申请人：——

  公开号：US20020016476A1

  公开（公告）日：2002-02-07

  Benzothiophenecarboxylic acid derivatives of the formula (I) which are useful as starting materials for producing drugs, and a process for preparing 5-hydroxybenzo[b]-thiophene-3-carboxylic acid derivatives of the formula (VI) which are specific PGD 2 antagonists. 1

  公式（I）的苯并噻吩羧酸衍生物可用作制药的起始物质，公式（VI）的5-羟基苯并[b]噻吩-3-羧酸衍生物是特异的PGD2拮抗剂的制备方法。

表征谱图